AHA Welcomes Antigenesis, Developing New Cancer Therapies for Pets.

Founded in February 2024, Antigenesis is focused on developing targeted cancer therapies for dogs and cats. The company is entering a young but fast-growing area of veterinary medicine, where antibody-based cancer therapies are only just beginning to emerge. 

Antigenesis is taking a smart and practical approach. The team adapts proven human antibodies for use in animals, supported by AI- and machine-learning-based design tools. This helps reduce development risk and speed up the path to market. With both public and private funding secured, Antigenesis already has the cancer molecules in preclinical development.

The opportunity is significant. The global veterinary oncology market is now valued at over £10 billion, with a projected £1 billion serviceable obtainable market by 2030 across multiple cancer indications.

Antigenesis commented:

“While others have taken the first step with canine antibodies, we are building the next generation of cancer therapies for dogs and cats. Our therapies are smarter, more targeted, and designed for deeper impact. By adapting proven human biologics and leveraging advanced design tools, Antigenesis is set to transform the future of veterinary oncology.”

From AHA’s side, Nick Park added:

“As the lead from the AHA side, I've really enjoyed getting to know Hugh and Ciaran and learning more about their work. There seems to be great potential in their model, and I look forward to helping them further in the future as they progress.”

Antigenesis is a strong addition to the AHA portfolio, combining scientific depth with a clear focus on real clinical need. We look forward to supporting the team as they continue to build their pipeline and bring new cancer treatments to companion animals.ad